查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722862

基因治療市場規模、佔有率、趨勢及預測（按基因類型、載體類型、遞送方式、應用和地區），2025 年至 2033 年

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球基因治療市場規模價值 58 億美元。展望未來， IMARC Group估計到 2033 年市場規模將達到 179 億美元，2025 年至 2033 年的複合年成長率為 13.3%。北美目前佔據市場主導地位，到 2024 年市佔率將超過 56%。北美市場受到強大的醫療保健基礎設施、不斷增加的研究營運投資、先進的監管框架以及促進創新的領先生物技術公司的推動。

基因治療市場分析：

市場成長和規模：受基因異常和罕見疾病盛行率上升的推動，該行業正在迅速擴張。此外，製藥企業正在增加對研發活動的投資，這對市場產生了積極影響。

技術進步：病毒載體技術的發展正在提高基因治療的有效性和安全性。此外，CRISPR-Cas9技術提高了基因編輯能力，進一步加速了基因治療市場統計。

產業應用：基因療法用於治療多種疾病，包括癌症、遺傳問題和自體免疫疾病。體外基因療法，在體外操縱細胞，在治療特定遺傳疾病方面越來越受歡迎。

地理趨勢：根據 IMARC 的基因療法市場統計數據，北美憑藉其強大的醫療保健基礎設施和發達的生物技術部門佔據市場主導地位。然而，在龐大患者群體的推動下，亞太地區正成為一個快速擴張的市場。

競爭格局：領先的企業正在進行全面的臨床研究，以開發並獲得針對各種疾病（包括罕見基因異常和癌症）的新型基因治療方法的監管批准。市場上一些主要的參與者包括 Abeona Therapeutics Inc.、Adaptimmune Therapeutics plc、Adverum Biotechnologies Inc.、Amgen Inc.、Astellas Pharma Inc.、Biogen Inc.、Bluebird Bio Inc.、Mustang Bio Inc. (Fortress Biotech Inc.)、Novartis AGager、Oraptisc.

挑戰與機會：雖然該行業面臨監管限制和高昂研究成本等限制，但它也期望能夠增加除罕見疾病之外的用途並研究新的交付方式。

未來展望：基因治療市場前景預計是正面的，對基因異常和罕見疾病的新療法的需求不斷成長。此外，針對獨特患者特徵的個人化基因療法預計將推動市場擴張。

基因治療市場趨勢：

病毒載體技術的進展

病毒載體技術的不斷進步和創新是推動市場成長的重要因素。病毒載體被用作運載工具，將治療基因引入患者的細胞。該技術的最新進展大大提高了基因治療的安全性和有效性。這些發展包括創建更具體、更集中的病毒載體，例如腺相關病毒 (AAV) 和慢病毒，其中 AAV 因其能夠以最小的免疫反應和損傷運輸遺傳物質而越來越受歡迎。此外，根據基因治療市場概況，研究人員正專注於開發可能攜帶更大遺傳負荷的病毒載體，擴大可治癒疾病的範圍。這些技術創新不僅提高了基因治療的療效，而且最大限度地減少了副作用的可能性，使患者更加安全。因此，病毒載體技術的進步正在加速基因治療對更廣泛的醫療問題的接受和療效。例如，默克集團 (MERCK KGaA) 的 VirusExpress 293 腺相關病毒 (AAV) 生產平台提供完整的病毒載體製造，包括 AAV 和慢病毒載體。此外，Catalent Inc. 推出了 UpTempo Virtuoso 平台流程，用於開發和製造腺相關病毒 (AAV) 載體。

研發投資與資金

基因治療研究和開發（R&D）工作不斷成長的投資和資金正在推動市場擴張。製藥公司、生技公司和政府機構正在投入大量資源開發基因治療技術和療法。基因治療在解決未滿足的醫療需求和提供長期利益方面具有巨大潛力，正在吸引大量資金。大型製藥公司要么收購基因治療新創公司，要么建立自己的基因治療部門以加快研究速度，這對基因治療市場前景產生了積極影響。此外，政府補助和激勵措施鼓勵學術機構和研究公司進行基因治療實驗。美國的《孤兒藥法案》以及其他國家的類似立法都為罕見疾病藥物的開發提供了誘因。例如，囊性纖維化基金會報告已投資 SalioGen Therapeutics，以支持該公司對囊性纖維化新型基因療法的臨床前研究。 Salonen 的基因編碼方法旨在開啟、關閉或修改基因組中任何基因的功能。

遺傳性疾病和罕見疾病的盛行率不斷上升

基因異常和罕見疾病的盛行率不斷上升，推動著市場的成長。許多此類疾病幾乎沒有或根本沒有有效的治療選擇，因此基因療法成為有趣的替代方法。隨著我們對遺傳學認知的不斷進步，越來越多的人得到診斷，對新型藥物的需求也不斷成長。此外，基因療法能夠透過修復或替換缺陷基因來治療許多疾病的根本原因。這包括肌肉營養不良症、囊性纖維化和其他遺傳性代謝失調等疾病。製藥和生物技術企業正在投資基因療法研究以滿足不斷成長的醫療需求，從而促進該領域的市場擴張和改善。例如，根據美國疾病管制與預防中心關於脊髓性肌肉萎縮症 (SMA) 的文章，SMA 是一種遺傳性疾病，每 10,000 人中約有 1 人患有此病。因此，它是最常見的罕見疾病之一。

支持性監管環境

一些國家的監管機構，尤其是美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA），都認知到基因療法滿足基本醫療需求的潛力。因此，他們創建了結構並加速了基因治療的研究和批准。此外，快速通道指定、突破性治療指定和孤兒藥地位是基因治療候選藥物可獲得的監管措施之一。這些指定簡化了臨床試驗程序，縮短了開發時間表，並鼓勵企業參與基因治療研究。例如，美國 FDA 批准了 Zynteglo（betibeglogene autotemcel），這是第一個用於治療成人和兒童BETA-地中海貧血患者的基於細胞的基因療法。由於基因療法的發展，此類批准預計將推動市場成長。

基因治療市場細分：

依基因類型分類：

抗原

細胞因子

腫瘤抑制因子

自殺基因

不足

生長因子

受體

其他

抗原基因是基因治療中的關鍵環節，尤其是在癌症免疫治療中。這些基因編碼腫瘤特異性抗原或與傳染性病原體相關的抗原。透過將抗原基因引入患者的細胞，可以活化免疫系統來識別和瞄準癌細胞或病原體。它們還能實現個人化癌症治療，透過針對患者特定的抗原來實現更有效、更有針對性的免疫反應。例如，Imugene 報告了與美國新澤西州凱尼爾沃思默克公司 (Merck & Co., Inc.) 的商標 MSD 達成的一項新的臨床試驗合作和供應協議，以評估 Imugene 的 HER-Vaxx（一種 B 細胞激活免疫療法）與 MSD 的抗 PD-1 療法 pembrolizumab (KEYmbrolizumab (KEYAUDA)。

依向量類型分類：

病毒載體

腺病毒

慢病毒

逆轉錄病毒

腺相關病毒

單純皰疹病毒

痘病毒

痘苗病毒

其他

非病毒技術

裸載體和質粒載體

基因槍

電穿孔

脂質體轉染

其他

病毒載體在產業中佔有最大的佔有率。

病毒載體，例如腺相關病毒 (AAV) 和慢病毒，由於能夠有效地將治療基因遞送到目標細胞中而越來越受到關注。 AAV 因其安全性和將遺傳物質整合到宿主基因組中的能力而受到青睞。它們廣泛用於各種基因治療應用，包括治療遺傳疾病、罕見疾病和某些類型的癌症。病毒載體技術的持續研究和進步正在推動這一領域的成長，許多臨床試驗和批准的療法都利用病毒載體。例如，美國FDA加速批准了慢病毒載體基因療法SKYSONA，證實可減緩4-17歲男孩的神經退化性功能障礙或活動性大腦腎上腺腦白質營養不良的進展。

依交付方式分類：

體內基因治療

體外基因治療

體內基因治療涉及將治療基因或遺傳物質直接輸送到患者體內。此方法旨在修改或糾正患者自然生理環境中組織或器官內的基因缺陷。體內基因治療方法通常利用病毒載體（例如腺相關病毒（AAV）或慢病毒）來運輸治療基因。基因治療的這一部分通常用於需要全身性治療的疾病，例如某些類型的遺傳性疾病或體內目標組織易於接近的疾病。例如，基因補充療法的最新進展正在擴大治療神經系統疾病的選擇。在可用的遞送載體中，腺相關病毒（AAV）通常是最受歡迎的載體。

按應用分類：

腫瘤疾病

罕見疾病

心血管疾病

神經系統疾病

傳染病

其他

腫瘤疾病佔據了大部分市場。

基因治療對多種癌症，包括實體腫瘤和血液系統惡性腫瘤，均有治療效果。方法包括引入腫瘤抑制基因和活化免疫系統對抗癌細胞。 CAR-T 細胞療法是一種基因療法，因其在治療某些類型的白血病和淋巴瘤方面的成功而受到關注。腫瘤疾病基因療法的持續研發活動正在推動市場成長。例如，美國 FDA 批准了 Abecma（idecabtagene vicleucel），這是一種基於細胞的基因療法，用於治療對至少四線（不同類型）治療無反應或病情復發的多發性骨髓瘤成年患者。 Abecma 是 FDA 批准的首個用於治療多發性骨髓瘤的細胞基因療法。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美引領市場，佔據最大的基因治療市場。

市場研究報告也對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告顯示，北美佔據最大的市場佔有率。

北美擁有強大的醫療保健基礎設施、成熟的生物技術產業以及對基因治療研發（R&D）的大量投資。有利的監管政策，包括快速通道指定和孤兒藥地位，正在加速基因療法的批准和商業化。基因治療市場的關鍵參與者總部設在北美，為該地區在基因治療創新領域的領導地位做出了貢獻。例如，根據美國國立衛生研究院（NIH）的最新消息，NIH、美國食品藥物管理局、十家製藥公司和五個非營利組織已合作加速為 3,000 萬名患有罕見疾病的美國人開發基因療法。預計這些措施將增加對基因治療的需求，進而促進市場成長。

競爭格局：

目前，主要產業競爭對手正在參與多項策略性措施。這些公司透過研究、收購和合作不斷擴大其基因治療組合。他們正在進行全面的臨床研究，以開發並獲得監管部門的批准，用於治療多種疾病，包括罕見的基因異常和癌症。此外，他們還投資製造設施以提高產量並確保更多的患者能夠獲得基因治療。此外，這些行業巨頭正在與學術機構和小型生物技術企業合作，以促進創新並改進基因治療技術。

市場研究報告對競爭格局進行了全面的分析。也提供了所有主要公司的詳細資料。市場中的一些主要參與者包括：

Abeona治療公司

Adaptimmune Therapeutics plc

Adverum 生技公司

安進公司

安斯泰來製藥公司

百健公司

藍鳥生物公司

Mustang Bio公司（Fortress Biotech公司）

諾華公司

Orchard Therapeutics plc

UniQure NV

Voyager Therapeutics公司

（請注意，這只是關鍵參與者的部分列表，完整列表在報告中提供。）

基因治療市場新聞：

2023 年 1 月：Spark Therapeutics 與 Neurochase 建立策略合作關係，開發 Neurochase 獨特的傳遞技術，用於治療中樞神經系統罕見疾病的選擇性基因治療。根據該協議，Neurochase 將向 Spark 的頂級 AAV 平台貢獻其在直接藥物傳輸技術方面的豐富知識。

2023 年 1 月：Voyager Therapeutics 和 Neurocrine Biosciences 達成策略合作，旨在實現 Voyager 的 GBA1 計劃以及其他針對神經系統疾病的下一代基因療法的商業化和開發。

2023 年 6 月：美國 FDA 核准 Sarepta 使用 ELEVIDYS 基因療法治療 4-5 歲兒童的 DMD。

2023 年 5 月：Krystal Biotech 的 VYJUVEK 基因療法獲得批准，用於治療營養不良性大皰性表皮鬆解症。

2023 年 12 月：瑞士治療產品管理局核准 Libmeldy 用於治療早發性異染性腦白質營養不良症。

2024 年 1 月：Biogen 和 Ginkgo Bioworks 宣布完成涉及基於 AAV 的載體的基因治療合作。預計這將在未來幾年推動對基因療法的需求。

本報告回答的關鍵問題

  • 什麼是基因治療
  • 全球基因療法市場有多大
  • 2025-2033年全球基因治療市場的預期成長率是多少
  • 推動全球基因治療市場的關鍵因素有哪些
  • 根據基因類型，全球基因治療市場的主要細分領域是什麼
  • 根據載體類型，全球基因治療市場的主要細分領域是什麼
  • 根據交付方式，全球基因治療市場的主要細分領域是什麼
  • 根據應用，全球基因治療市場的主要細分領域是什麼
  • 全球基因治療市場的主要區域有哪些
  • 10.全球基因治療市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 什麼是基因治療？全球基因治療市場有多大？
  • 2025-2033年全球基因治療市場的預期成長率是多少？
  • 推動全球基因治療市場發展的關鍵因素有哪些？
  • 根據基因類型，全球基因治療市場的主要部分是什麼？
  • 根據載體類型，全球基因治療市場的主要部分是什麼？
  • 根據交付方式，全球基因治療市場的主要部分是什麼？
  • 根據應用，全球基因治療市場的主要部分是什麼？
  • 全球基因治療市場的主要區域有哪些？
  • 全球基因治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球基因治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依基因類型

  • 抗原
  • 細胞因子
  • 腫瘤抑制因子
  • 自殺基因
  • 不足
  • 生長因子
  • 受體
  • 其他

第7章：市場區隔：依向量類型

  • 病毒載體
    • 關鍵部分
      • 腺病毒
      • 慢病毒
      • 逆轉錄病毒
      • 腺相關病毒
      • 單純皰疹病毒
      • 痘病毒
      • 痘苗病毒
      • 其他
  • 非病毒技術
    • 關鍵部分
      • 裸載體和質粒載體
      • 基因槍
      • 電穿孔
      • 脂質體轉染
      • 其他

第8章：市場區隔：依交付方式

  • 體內基因治療
  • 體外基因治療

第9章：市場區隔：依應用

  • 腫瘤疾病
  • 罕見疾病
  • 心血管疾病
  • 神經系統疾病
  • 傳染病
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics plc
    • Adverum Biotechnologies Inc.
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.
    • Bluebird Bio Inc.
    • Mustang Bio Inc. (Fortress Biotech Inc.)
    • Novartis AG
    • Orchard Therapeutics plc
    • UniQure NV
    • Voyager Therapeutics Inc.
Product Code: SR112025A5026

The global gene therapy market size was valued at USD 5.8 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 17.9 Billion by 2033, exhibiting a CAGR of 13.3% from 2025-2033. North America currently dominates the market, holding a market share of over 56% in 2024. The North American market is driven by robust healthcare infrastructure, rising investments in research operations, advanced regulatory frameworks, and the presence of leading biotechnology firms fostering innovation.

Gene Therapy Market Analysis:

Market Growth and Size: The industry is expanding rapidly, fueled by the rising prevalence of genetic abnormalities and rare diseases. Additionally, pharmaceutical businesses are increasingly investing in research and development (R&D) activities, which are positively impacting the market.

Technological Advancements: Developments in viral vector technology are enhancing the efficacy and safety of gene therapy delivery. Moreover, CRISPR-Cas9 technology improves gene editing capabilities, which further accelerates gene therapy market statistics.

Industry Applications: Gene therapy is used to treat a variety of ailments, including cancer, genetic problems, and autoimmune conditions. Ex vivo gene therapy, in which cells are manipulated outside the body, is gaining popularity for treating specific genetic illnesses.

Geographical Trends: As per the gene therapy market statistics by IMARC, North America dominates the market, owing to its strong healthcare infrastructure and developed biotechnology sector. However, Asia Pacific is emerging as a rapidly expanding market, propelled by a big patient population.

Competitive Landscape: Leading players are conducting comprehensive clinical studies to develop and get regulatory clearance for novel gene treatments aimed at a variety of ailments, including rare genetic abnormalities and cancer. Some of the key players in the market include Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V., Voyager Therapeutics Inc., etc.

Challenges and Opportunities: While the industry confronts constraints like regulatory limitations and high research costs, it also expects possibilities for increasing uses beyond rare disorders and investigating novel delivery modalities.

Future Outlook: The gene therapy market outlook is expected to be positive, with rising demand for novel therapies for genetic abnormalities and uncommon illnesses. Furthermore, individualized gene therapy tailored to unique patient characteristics is projected to drive market expansion.

Gene Therapy Market Trends:

Advancements in Viral Vector Technology

Continuous progress and innovation in viral vector technology are important factors driving market growth. Viral vectors are used as delivery vehicles to introduce therapeutic genes into the cells of patients. Recent advances in this technique have greatly improved the safety and efficacy of gene therapy therapies. These developments include the creation of more specific and focused viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, with AAVs gaining popularity due to their ability to transport genetic material with minimal immune reaction and damage. Furthermore, as per the gene therapy market overview, researchers are focusing on developing viral vectors that may carry bigger genetic payloads, broadening the range of curable disorders. These technical innovations not only increase the efficacy of gene treatments but also minimize the likelihood of adverse effects, making them safer for patients. As a result, the advancement of viral vector technology is accelerating the acceptance and efficacy of gene therapy treatments for a broader range of medical problems. For instance, MERCK KGaA, the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, offers full viral vector manufacturing, including AAV and lentiviral vectors. Additionally, Catalent Inc. launched UpTempo Virtuoso platform process for the development and manufacturing of adeno-associated viral (AAV) vectors.

Investment And Funding in Research and Development

The growing investments and funding for gene therapy research and development (R&D) efforts are driving market expansion. Pharmaceutical businesses, biotechnology firms, and government agencies are putting major resources into developing gene therapy technologies and therapeutics. Gene treatments have a strong potential for addressing unmet medical needs and providing long-term benefits, which is drawing significant funding. Major pharmaceutical corporations are either purchasing gene therapy startups or building their own gene therapy sections to speed up research, which is positively impacting the gene therapy market outlook. Furthermore, government subsidies and incentives motivate academic institutions and research firms to conduct gene therapy experiments. The Orphan Drug Act in the United States, as well as comparable legislation in other countries, gives incentives for the development of rare illness medicines. For instance, the Cystic Fibrosis Foundation reported investing in SalioGen Therapeutics to support the company's preclinical research into novel gene therapy for cystic fibrosis. Salonen's Gene Coding approach is designed to turn on, turn off, or modify the function of any gene in the genome.

Rising Prevalence of Genetic Disorders and Rare Diseases

The rising prevalence of genetic abnormalities and rare illnesses is propelling the market growth. Many of these diseases have little or no effective treatment choices, making gene therapy an intriguing alternative. As our understanding of genetics advances, more people are diagnosed, and the demand for novel medicines grows. Moreover, gene therapy has the ability to treat the underlying causes of many disorders by repairing or replacing defective genes. This comprises illnesses including muscular dystrophy, cystic fibrosis, and other hereditary metabolic disorders. Pharmaceutical and biotechnology businesses are investing in gene therapy research to fulfill this expanding medical demand, resulting in market expansion and improvements in the area. For instance, as per the United States Center for Disease Control and Prevention article on spinal muscular atrophy (SMA), SMA is a genetic disorder that affects around 1 in every 10,000 people. Therefore, it is one of the most common rare diseases.

Supportive Regulatory Environment

Regulatory organizations in several countries, especially the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), recognize the potential of gene therapy to address essential medical needs. Consequently, they have created structures and accelerated the research and approval of gene treatments. Additionally, fast-track designations, breakthrough treatment designations, and orphan drug status are among the regulatory measures available to gene therapy candidates. These designations ease the clinical trial procedure, shorten development schedules, and encourage corporations to participate in gene therapy research. For instance, the U.S. FDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for treating adult and pediatric patients with beta-thalassemia. Such approvals are expected to drive market growth due to the rise in the development of gene therapies.

Gene Therapy Market Segmentation:

Breakup by Gene Type:

Antigen

Cytokine

Tumor Suppressor

Suicide Gene

Deficiency

Growth Factors

Receptors

Others

Antigen genes are a critical segment in gene therapy, especially in the context of cancer immunotherapy. These genes code for tumor-specific antigens or antigens associated with infectious agents. By introducing antigen genes into the cells of the patients, the immune system can be activated to recognize and target cancer cells or pathogens. They also enable personalized cancer treatments, where patient-specific antigens can be targeted for a more effective and targeted immune response. For instance, Imugene reported a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in patients with HER-2 positive gastric cancer.

Breakup by Vector Type:

Viral Vector

Adenoviruses

Lentiviruses

Retroviruses

Adeno-Associated Virus

Herpes Simplex Virus

Poxvirus

Vaccinia Virus

Others

Non-Viral Techniques

Naked and Plasmid Vectors

Gene Gun

Electroporation

Lipofection

Others

Viral vector holds the largest share in the industry.

Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, are gaining traction due to their efficient delivery of therapeutic genes into target cells. AAVs are favored for their safety profile and ability to integrate genetic material into the host genome. They are widely used for a variety of gene therapy applications, including treating genetic disorders, rare diseases, and certain types of cancer. Ongoing research and advancements in viral vector technology are driving the growth of this segment, with numerous clinical trials and approved therapies utilizing viral vectors. For instance, the U.S. FDA granted approval at an accelerated pace for SKYSONA- a lentiviral vector gene therapy shown to slow the progression of neurodegenerative dysfunction, or active cerebral adrenoleukodystrophy in boys with the age range of 4-17.

Breakup by Delivery Method:

In-Vivo Gene Therapy

Ex-Vivo Gene Therapy

In-vivo gene therapy involves the direct delivery of therapeutic genes or genetic material into the body of the patient. This approach aims to modify or correct genetic defects within the tissues or organs of patients in their natural physiological environment. In-vivo gene therapy methods typically utilize viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, to transport the therapeutic genes. This segment of gene therapy is often used for diseases that require systemic treatment, such as certain types of inherited disorders or conditions where the target tissue is easily accessible within the body. For instance, recent advancements in gene supplementation therapy are expanding the options for the treatment of neurological disorders. Among the available delivery vehicles, adeno-associated virus (AAV) is often the favored vector.

Breakup by Application:

Oncological Disorders

Rare Diseases

Cardiovascular Diseases

Neurological Disorders

Infectious Disease

Others

Oncological disorders account for the majority of the market share.

Gene therapy is effective in the treatment of various cancers, including solid tumors and hematological malignancies. Approaches range from introducing tumor-suppressing genes to activating the immune system against cancer cells. CAR-T cell therapy, a type of gene therapy, is gaining traction for its success in treating certain types of leukemia and lymphoma. The ongoing research and development (R&D) activities of gene therapies for oncological disorders are impelling the market growth. For instance, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after at least four last lines (different types) of treatment. Abecma is the first cell-based gene therapy approved by the FDA for treating multiple myeloma.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest gene therapy market share.

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a robust healthcare infrastructure, a well-established biotechnology industry, and significant investment in gene therapy research and development (R&D). Favorable regulatory policies, including fast-track designations and orphan drug status, are accelerating the approval and commercialization of gene therapies. Key players in the gene therapy market are headquartered in North America, contributing to the leadership of the region in gene therapy innovations. For instance, as per an update by the National Institutes of Health (NIH), the NIH, USFDA, ten pharmaceutical companies, and five non-profit organizations have partnered to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are anticipated to increase the demand for gene therapy, thereby contributing to market growth.

Competitive Landscape:

Key industry competitors are currently involved in a number of strategic initiatives. These firms are constantly growing their gene therapy portfolios via research, acquisitions, and collaborations. They are undertaking comprehensive clinical studies to develop and get regulatory clearance for novel gene treatments that will treat a variety of ailments, including rare genetic abnormalities and cancer. In addition, they are investing in manufacturing facilities to increase output and ensure gene treatments are available to a larger patient population. Furthermore, these industry heavyweights are pursuing collaborations with academic institutions and smaller biotech businesses to promote innovation and improve gene therapy technology.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abeona Therapeutics Inc.

Adaptimmune Therapeutics plc

Adverum Biotechnologies Inc.

Amgen Inc.

Astellas Pharma Inc.

Biogen Inc.

Bluebird Bio Inc.

Mustang Bio Inc. (Fortress Biotech Inc.)

Novartis AG

Orchard Therapeutics plc

UniQure N.V.

Voyager Therapeutics Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Gene Therapy Market News:

January 2023: Spark Therapeutics and Neurochase established a strategic collaboration to develop Neurochase's unique delivery technology for use with selected gene treatments for rare disorders in the CNS. In this agreement, Neurochase will contribute its extensive knowledge in direct drug delivery technology to Spark's premier AAV platform.

January 2023: Voyager Therapeutics and Neurocrine Biosciences entered into a strategic collaboration for the commercialization & development of Voyager's GBA1 program and other next-generation gene therapies for neurological diseases.

June 2023: The U.S. FDA granted approval to Sarepta for ELEVIDYS gene therapy to treat DMD in children of age 4-5 years.

May 2023: Krystal Biotech was granted approval for VYJUVEK gene therapy for Dystrophic Epidermolysis Bullosa treatment.

December 2023: Swiss Agency for Therapeutic Products granted approval to Libmeldy for the treatment of early-onset metachromatic leukodystrophy.

January 2024: Biogen and Ginkgo Bioworks announced that they have completed the gene therapy collaboration involving AAV-based vectors. This is expected to fuel the demand for gene therapies in the coming years.

Key Questions Answered in This Report

  • 1.What is gene therapy?
  • 2.How big is the global gene therapy market?
  • 3.What is the expected growth rate of the global gene therapy market during 2025-2033?
  • 4.What are the key factors driving the global gene therapy market?
  • 5.What is the leading segment of the global gene therapy market based on gene type?
  • 6.What is the leading segment of the global gene therapy market based on vector type?
  • 7.What is the leading segment of the global gene therapy market based on delivery method?
  • 8.What is the leading segment of the global gene therapy market based on application?
  • 9.What are the key regions in the global gene therapy market?
  • 10.Who are the key players/companies in the global gene therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gene Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Gene Type

  • 6.1 Antigen
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cytokine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Tumor Suppressor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Suicide Gene
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Deficiency
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Growth Factors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Receptors
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Vector Type

  • 7.1 Viral Vector
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Adenoviruses
      • 7.1.2.2 Lentiviruses
      • 7.1.2.3 Retroviruses
      • 7.1.2.4 Adeno-Associated Virus
      • 7.1.2.5 Herpes Simplex Virus
      • 7.1.2.6 Poxvirus
      • 7.1.2.7 Vaccinia Virus
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Non-Viral Techniques
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Naked and Plasmid Vectors
      • 7.2.2.2 Gene Gun
      • 7.2.2.3 Electroporation
      • 7.2.2.4 Lipofection
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Delivery Method

  • 8.1 In-Vivo Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ex-Vivo Gene Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Oncological Disorders
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rare Diseases
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Cardiovascular Diseases
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Neurological Disorders
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Infectious Disease
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Others
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abeona Therapeutics Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Adaptimmune Therapeutics plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Adverum Biotechnologies Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Amgen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Astellas Pharma Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Biogen Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Bluebird Bio Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Mustang Bio Inc. (Fortress Biotech Inc.)
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Orchard Therapeutics plc
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 UniQure N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
    • 15.3.12 Voyager Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials

List of Figures

  • Figure 1: Global: Gene Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Gene Therapy Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Gene Therapy Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Gene Therapy Market: Breakup by Gene Type (in %), 2024
  • Figure 5: Global: Gene Therapy Market: Breakup by Vector Type (in %), 2024
  • Figure 6: Global: Gene Therapy Market: Breakup by Delivery Method (in %), 2024
  • Figure 7: Global: Gene Therapy Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Gene Therapy Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Gene Therapy (Antigen) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Gene Therapy (Antigen) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Gene Therapy (Cytokine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Gene Therapy (Cytokine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Gene Therapy (Tumor Suppressor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Gene Therapy (Tumor Suppressor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Gene Therapy (Suicide Gene) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Gene Therapy (Suicide Gene) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Gene Therapy (Deficiency) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Gene Therapy (Deficiency) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Gene Therapy (Growth Factors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Gene Therapy (Growth Factors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Gene Therapy (Receptors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Gene Therapy (Receptors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Gene Therapy (Other Gene Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Gene Therapy (Other Gene Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Gene Therapy (Viral Vector) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Gene Therapy (Viral Vector) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Gene Therapy (Non-Viral Techniques) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Gene Therapy (Non-Viral Techniques) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Gene Therapy (In-Vivo Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Gene Therapy (In-Vivo Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Gene Therapy (Oncological Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Gene Therapy (Oncological Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Gene Therapy (Rare Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Gene Therapy (Rare Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Gene Therapy (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Gene Therapy (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Gene Therapy (Neurological Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Gene Therapy (Neurological Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Gene Therapy (Infectious Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Gene Therapy (Infectious Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Gene Therapy (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Gene Therapy (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia-Pacific: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia-Pacific: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Gene Therapy Market: Breakup by Country (in %), 2024
  • Figure 93: Middle East and Africa: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Gene Therapy Industry: SWOT Analysis
  • Figure 95: Global: Gene Therapy Industry: Value Chain Analysis
  • Figure 96: Global: Gene Therapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gene Therapy Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Gene Therapy Market Forecast: Breakup by Gene Type (in Million USD), 2025-2033
  • Table 3: Global: Gene Therapy Market Forecast: Breakup by Vector Type (in Million USD), 2025-2033
  • Table 4: Global: Gene Therapy Market Forecast: Breakup by Delivery Method (in Million USD), 2025-2033
  • Table 5: Global: Gene Therapy Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Gene Therapy Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Gene Therapy Market: Competitive Structure
  • Table 8: Global: Gene Therapy Market: Key Players